Grifols Plans U.S. IPO for Biopharma Business to Cut Debt and Boost Growth
Grifols has approved a U.S. IPO of a minority stake in its Biopharma business.
/ 1659 items
#XY↓
Clear Street: Gilead Deal Highlights Huge Potential in Cullinan’s Pipeline
Gilead’s up to $2.2B acquisition of Ouro Medicines highlights strong potential for Cullinan Therapeutics’ velinotamig. Clear Street maintains Buy rating with $33 PT.
Wall Street Goes Bullish on Sutro Biopharma: Two Major Upgrades After Q4 Results
Wells Fargo upgrades to Overweight with $27 PT and H.C. Wainwright raises to Buy with $28 target on strong STRO-004 progress.
Immunic Gets Buy Rating from Guggenheim – Dual-Action MS Pill Shows Strong Potential
Guggenheim launches coverage on Immunic at Buy with a $7 target. The dual-action MS drug vidofludimus calcium targets both inflammation and nerve protection – Phase 3 data could drive major gains.
FDA Slaps ImmunityBio with Warning Letter Over Misleading ANKTIVA Ads
ImmunityBio shares dropped 20% after the FDA issued a warning letter accusing the company of false claims that ANKTIVA cures all cancers.
Goldman Sachs Downgrades Ultragenyx to Neutral After Setrusumab Trial Miss
Goldman Sachs downgraded Ultragenyx from Buy to Neutral and slashed its price target to $25 after setrusumab Phase 3 miss in osteogenesis imperfecta. GTX-102 in Angelman syndrome now key focus, but risks remain.